Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Lilja

Showing results (1-10 of 305) with videos related to

Pageof 31
Sort By:
Urology|November 11, 2003
Biology of prostate-specific antigenHans Lilja
Clinical Chemistry|July 3, 2008
Testing new PSA subforms to enhance the accuracy of predicting cancer risk and disease outcome in prostate cancerHans Lilja
Scandinavian Journal of Urology|October 4, 2021
Modern prostate cancer diagnostics reduce overdiagnosis - will they open up for population-based screening?Ola Bratt, Hans Lilja
Current Opinion in Urology|November 14, 2014
Serum markers in prostate cancer detectionOla Bratt, Hans Lilja
Urology|November 9, 2010
Editorial comment. Association between glomerular filtration rate, free, total, and percent free prostate-specific antigenAnders Christensson, Hans Lilja
European Urology|June 27, 2016
Circulating Tumor Cell Count as an Indicator of Treatment Benefit in Advanced Prostate CancerDavid Neal, Hans Lilja
Nature Clinical Practice. Urology|May 24, 2007
Can PSA velocity predict risk of death in men with prostate cancer?Hans Lilja, Frank O'Brien
Urology|April 12, 2011
Editorial commentAmit Gupta, Hans Lilja
Urology|September 3, 2011
Editorial commentAndrew Vickers, Hans Lilja
Clinical Chemistry|August 3, 2010
Detection of androgen receptor mutations in circulating tumor cells: highlights of the long road to clinical qualificationHans Lilja, Howard I Scher
Pageof 31

Showing results (1-10 of 305) with videos related to

Sort By:
Pageof 31
Urology|November 11, 2003
Biology of prostate-specific antigenHans Lilja
Clinical Chemistry|July 3, 2008
Testing new PSA subforms to enhance the accuracy of predicting cancer risk and disease outcome in prostate cancerHans Lilja
Scandinavian Journal of Urology|October 4, 2021
Modern prostate cancer diagnostics reduce overdiagnosis - will they open up for population-based screening?Ola Bratt, Hans Lilja
Current Opinion in Urology|November 14, 2014
Serum markers in prostate cancer detectionOla Bratt, Hans Lilja
Urology|November 9, 2010
Editorial comment. Association between glomerular filtration rate, free, total, and percent free prostate-specific antigenAnders Christensson, Hans Lilja
European Urology|June 27, 2016
Circulating Tumor Cell Count as an Indicator of Treatment Benefit in Advanced Prostate CancerDavid Neal, Hans Lilja
Nature Clinical Practice. Urology|May 24, 2007
Can PSA velocity predict risk of death in men with prostate cancer?Hans Lilja, Frank O'Brien
Urology|April 12, 2011
Editorial commentAmit Gupta, Hans Lilja
Urology|September 3, 2011
Editorial commentAndrew Vickers, Hans Lilja
Clinical Chemistry|August 3, 2010
Detection of androgen receptor mutations in circulating tumor cells: highlights of the long road to clinical qualificationHans Lilja, Howard I Scher
Pageof 31